AstraZeneca has requested emergency use authorisation from U.S. regulators for its new treatment to prevent COVID-19.

The long-acting antibody (LAAB) combination is for prophylaxis of symptomatic COVID-19. It is aimed for people who respond poorly to vaccines because of a weakened immune system, Reuters reports.

The antibody therapy called AZD7442 could protect people who do not have a strong enough immune response to COVID-19 vaccines or to supplement a vaccination course for those, such as military personnel, who need to booster their protection further, AstraZeneca has said.

It may be the first LAAB to receive an EUA for COVID-19 prevention

If granted, AZD7442 would be the first LAAB to receive an EUA for COVID-19 prevention. It is the first LAAB with Phase III data demonstrating a statistically significant reduction in the risk of developing symptomatic COVID-19 compared to placebo.

Vulnerable populations such as the immunocompromised often aren’t able to mount a protect ...

...